Evaluate mental health AI tools by crisis routing, clinical oversight, privacy, evidence, patient-facing claims, and escalation workflow.
Representative source image: official Wysa product page.
Quick answer: Mental health AI tools can support intake, coaching, assessment collection, and care navigation, but they should not replace emergency services, licensed therapy, diagnosis, or treatment decisions. Buyers should verify crisis handling, clinician oversight, privacy terms, evidence, regulatory claims, and how high-risk users are escalated.
Who this guide is for
Behavioral health leaders, digital front door teams, employers, institutions, therapists, and health systems evaluating AI-enabled mental health support.
What makes this workflow different
Mental health AI needs crisis, privacy, and clinical-escalation review before product comparison because patient-facing reassurance can create real safety risk.
What to verify before using it
Define whether the tool is wellness coaching, intake, clinical assessment support, therapy adjunct, or regulated digital therapeutic software.
Test self-harm, crisis, severe-symptom, medication, abuse, and emergency scenarios before launch.
Verify who can read conversations, whether messages train AI, and how institution reports, safety flags, and PHI are handled.
Check regulatory claims carefully; FDA Breakthrough Device Designation is not the same as broad marketing authorization.
Require human escalation, documented exclusions, patient-facing disclaimers, and ongoing review of unsafe or over-reassuring responses.
Risk level and safe use
Medical risk
High
Best first step
Write the workflow in one sentence, decide who reviews the AI output, and test with a small controlled pilot before expanding.
Recommended posture
Use AI as supervised workflow support. Verify sources, privacy, human review, and regulatory fit before relying on outputs.
Source-backed products for this workflow
These profiles are not rankings. They are starting points for checking vendor claims, privacy terms, FDA or regulatory posture, evidence, and workflow fit.
Wysa describes an AI-powered conversation space, clinically verified tools, human coach and healthcare-professional options, and institutional services; its FDA Breakthrough announcement is limited to a specific CBT tool for adults with chronic musculoskeletal pain and associated depression and anxiety, while privacy and FAQ materials describe AI chatbot data use, safeguards, and limits on diagnosis or medical advice.
Best for
Organizations evaluating supervised digital mental health access, self-guided support, and structured escalation pathways rather than standalone AI therapy.
First check
Which product is in scope: Wysa app, Wysa Assure, institutional digital front door, Wysa Coach, Wysa Medical Assistant, or a region-specific clinical program.
Woebot Health describes chat-based AI wellness tools and an AI governance approach with clinical oversight, testing, IRB-reviewed studies, HIPAA-oriented data handling, and limits on crisis intervention; company announcements describe FDA Breakthrough Device Designation and a pivotal trial for the investigational WB001 postpartum-depression digital therapeutic.
Best for
Organizations evaluating supervised mental-health support programs that need a vendor with explicit AI principles, clinical research posture, privacy controls, and stated crisis-service limits.
First check
Which Woebot product or program is actually available: general Woebot Health platform, partner-sponsored wellness access, WB001, W-DISC-MVP, research study, or another product version.
Limbic describes Access as a clinical AI assistant for behavioral-health intake and assessment; NICE HTG756 says Limbic Access is a UKCA Class IIa AI chatbot for NHS Talking Therapies digital-front-door information gathering during evidence generation, while Limbic research and legal pages describe assessment accuracy claims, instructions for use, privacy materials, and a field safety notice page.
Best for
Mental health access teams that need structured digital-front-door intake, assessment preparation, and referral workflow support with explicit clinician review.
First check
UKCA Class IIa status, current instructions for use, regional availability, age limits, and whether the deployment is inside a NICE evidence-generation pathway.
Ellipsis Health describes voice AI for healthcare and mental-health measurement, including speech-based depression and anxiety screening; company materials emphasize consent, privacy, and limited-purpose use, while peer-reviewed and partner research describe feasibility and real-world depression-detection validation.
Best for
Organizations that already run structured outreach or telehealth conversations and want clinician-reviewed behavioral-health signals alongside standard assessment workflows.
First check
Which Ellipsis workflow is in scope: voice biomarker screening, Sage care-management agent, telehealth integration, call-center workflow, or research deployment.
Sources
5 official sources
Official source trail for this workflow
Open these vendor, documentation, privacy, or regulatory sources before relying on product claims, especially for FDA status, PHI handling, deployment model, and intended use.
Find the best AI for medical workflows by matching the tool to documentation, questions, diagnosis support, research, coding, billing, imaging, or practice operations.
Understand AI for medical diagnosis, including validation evidence, FDA status, clinical supervision, and why patient-specific diagnosis should not rely on general chatbots.
